Qube Research & Technologies (QRT)’s Viking Therapeutics VKTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,688	Closed	-$2.27M	–	4781
2024 Q1	$2.27M	Sell	27,688 -1,444	-5%	-$64.3K	﹤0.01%	1680
2023 Q4	$542K	Buy	+29,132	New	+$381K	﹤0.01%	2234
2022 Q4	–	Sell	-46,186	Closed	-$126K	–	3035
2022 Q3	$126K	Buy	46,186 +19,863	+75%	+$65.1K	﹤0.01%	1908
2022 Q2	$76K	Sell	26,323 -2,360	-8%	-$5.84K	﹤0.01%	2030
2022 Q1	$86K	Buy	28,683 +17,612	+159%	+$63.2K	﹤0.01%	2102
2021 Q4	$51K	Buy	+11,071	New	+$62K	﹤0.01%	2256
2021 Q1	–	Sell	-11,157	Closed	-$63K	–	2450
2020 Q4	$63K	Sell	11,157 -10,415	-48%	-$63.1K	﹤0.01%	1683
2020 Q3	$126K	Sell	21,572 -17,825	-45%	-$123K	﹤0.01%	1473
2020 Q2	$284K	Buy	+39,397	New	+$262K	﹤0.01%	1325

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VKTX Position: Q2 2024 in Review

Qube Research & Technologies (QRT) sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 27,688 shares — an estimated $2.27M sold.

Qube Research & Technologies (QRT) first reported a position in VKTX in Q2 2020 and held it in 9 quarters. The position peaked at $2.27M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Qube Research & Technologies (QRT) reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 27,688 Viking Therapeutics shares in Q2 2024, an estimated $2.27M.
Qube Research & Technologies (QRT) first reported a position in Viking Therapeutics in Q2 2020 and held it in 9 quarters.
Qube Research & Technologies (QRT)'s Viking Therapeutics position peaked at $2.27M in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2024, filed 14 Aug 2024.